

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Biocon Ltd</u> _____ (Last) (First) (Middle) 20TH KM, HOSUR ROAD ELECTRONIC CITY _____ (Street) BANGALORE K7 560100 _____ (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 09/12/2024	3. Issuer Name and Ticker or Trading Symbol <u>Bicara Therapeutics Inc.</u> [ BCAX ]	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) _____ 6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	115,757	I	By Biocon Limited <sup>(1)</sup>

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series Seed Redeemable Convertible Preferred Stock	(2)	(2)	Common Stock	4,327,365	(2)	I	By Biocon Limited <sup>(1)</sup>
Series Seed Redeemable Convertible Preferred Stock	(2)	(2)	Common Stock	1,080,775	(2)	I	By Biocon Pharma Inc. <sup>(3)</sup>

1. Name and Address of Reporting Person* <u>Biocon Ltd</u> _____ (Last) (First) (Middle) 20TH KM, HOSUR ROAD ELECTRONIC CITY _____ (Street) BANGALORE K7 560100 _____ (City) (State) (Zip)
--

1. Name and Address of Reporting Person* <u>Biocon Pharma Inc.</u> _____ (Last) (First) (Middle) 485 STATE HWY 1 SOUTH SUITE B 305 _____ (Street) ISELIN NJ 08830 _____ (City) (State) (Zip)
--

(City)

(State)

(Zip)

**Explanation of Responses:**

1. Shares held by Biocon Limited ("Biocon Ltd"). Kiran Mazumdar-Shaw is the managing member of Biocon Ltd. Each of the Reporting Persons and Ms. Mazumdar-Shaw disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any Reporting Person is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.

2. Each share of Series Seed Redeemable Convertible Preferred Stock (the "Preferred Stock") is convertible into Common Stock on a 9.2435-to-one basis at the option of the holder, and will convert automatically upon closing of the Issuer's initial public offering into the number of shares shown in column 3 without payment of consideration. The Preferred Stock has no expiration date.

3. Shares held by Biocon Pharma Inc. ("Biocon Pharma"). Kiran Mazumdar-Shaw is the managing member of Biocon Pharma. Each of the Reporting Persons and Ms. Mazumdar-Shaw disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any Reporting Person is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.

BIOCON LIMITED, By:  
/s/ Kiran Mazumdar-Shaw, 09/12/2024  
Title: Executive  
Chairperson

BIOCON PHARMA INC.,  
By: /s/ Abhijit Zutshi, 09/12/2024  
Title: Director

\*\* Signature of Reporting Person                      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**